Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Enanta Pharmaceuticals and keeping the price target at $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Enanta Pharmaceuticals’ promising outlook. The company is poised for significant data readouts, particularly with the upcoming Phase 2 results for zelicapavir in high-risk adults with Respiratory Syncytial Virus (RSV) infection, expected in September. This potential milestone, coupled with the company’s strong balance sheet, which includes approximately $204 million in cash and marketable securities, supports a favorable risk-reward profile for investors.
Enanta’s virology pipeline is a key focus, with promising candidates like zelicapavir and EDP-323, both of which have received Fast Track designation. The completion of enrollment in the RSVHR trial and the anticipated topline results further bolster confidence in the company’s strategic direction. Additionally, Enanta’s efforts in immunology, particularly the development of EPS-1421, an oral KIT inhibitor, demonstrate the company’s commitment to expanding its therapeutic offerings. These factors collectively underpin Folkes’s Buy rating, reflecting optimism about Enanta’s future growth and innovation potential.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $25.00 price target.